Long-Term Respiratory and Neurological Sequelae of COVID-19

Fuzhou Wang, Richard M Kream, George B Stefano, Fuzhou Wang, Richard M Kream, George B Stefano

Abstract

Since the initial reports of coronavirus disease 2019 (COVID-19) in China in late 2019, infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have spread rapidly, resulting in a global pandemic that has caused millions of deaths. Initially, the large number of infected people required the direction of global healthcare resources to provide supportive care for the acutely ill population in an attempt to reduce mortality. While clinical trials for safe and effective antiviral agents are ongoing, and vaccine development programs are being accelerated, long-term sequelae of SARS-CoV-2 infection have become increasingly recognized and concerning. Although the upper and lower respiratory tracts are the main sites of entry of SARS-CoV-2 into the body, resulting in COVID-19 pneumonia as the most common presentation, acute lung damage may be followed by pulmonary fibrosis and chronic impairment of lung function, with impaired quality of life. Also, increasing reports have shown that SARS-CoV-2 infection involves the central nervous system (CNS) and the peripheral nervous system (PNS) and directly or indirectly damages neurons, leading to long-term neurological sequelae. This review aims to provide an update on the mechanisms involved in the development of the long-term sequelae of SARS-CoV-2 infection in the 3 main areas of lung injury, neuronal injury, and neurodegenerative diseases, including Alzheimer disease, Parkinson disease, and multiple sclerosis, and highlights the need for patient monitoring following the acute stage of infection with SARS-CoV-2 to provide a rationale for the prevention, diagnosis, and management of these potential long-term sequelae.

Conflict of interest statement

Conflict of interest

None.

Figures

Figure 1
Figure 1
Respiratory injury associated with SARS-CoV-2 infection. SARS-CoV-2 induces inflammatory changes in all 3 main locations of the respiratory system from the trachea (A), to the bronchi (B), and the alveolar sacs (C). The respiratory system will experience acute inflammation following the pro-inflammatory ‘cytokine storm,’ followed by long-term fibrotic changes. Pulmonary fibrosis is associated with the upregulation of transforming growth factor-beta (TGF-β) and chronic inflammation.
Figure 2
Figure 2
Neuronal injury associated with SARS-CoV-2 infection. SARS-CoV-2 enters into the central nervous system (CNS) through 2 major routes: the olfactory pathway (#1 in A), and the blood–brain barrier (BBB) pathway (#2 in A). The virus can migrate into the CNS directly by endocytosis with the assistance of inflammatory cytokine-induced increased vascular permeability and indirect transfer via a ‘Trojan horse’ mechanism. (B) After binding to its membrane receptor, ACE2, SARS-CoV-2 will be engulfed into neuronal cytosol and move to connect with cytosol-located angiotensin-converting enzyme 2 (ACE2). The viral RNAs enter the mitochondria or form into autophagolysosomes to initiate autophagy and/or apoptosis. Microglia and immune cells produce pro-inflammatory cytokines, which result in further abnormalities in mitochondrial function. When the virus enters the neurons, it combines with the axonal microtubules with anterograde and retrograde spread to the synapse and enters the next level of neurons by trans-synaptic transfer and endocytosis. Both the virus and the ‘cytokine storm’ can destroy the myelin sheath of neurons, resulting in acute and chronic neuropathology.

References

    1. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) – recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–11.
    1. Wang F, Kream RM, Stefano GB. An evidence-based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monitm. 2020;26:e924700.
    1. Oldfield E, Malwal SR. COVID-19 and other pandemics: How might they be prevented? ACS Infect Dis. 2020;6(7):1563–66.
    1. Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) J Pathol. 2020;251(3):228–48.
    1. Helms J, Tacquard C, Severac F, et al. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis) High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.
    1. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807–15.
    1. Stefano ML, Kream RM, Stefano GB. A novel vaccine employing non-replicating rabies virus expressing chimeric SARS-CoV-2 spike protein domains: functional inhibition of viral/nicotinic acetylcholine receptor complexes. Med Sci Monit. 2020;26:e926016.
    1. Singal CMS, Jaiswal P, Seth P. SARS-CoV-2, more than a respiratory virus: Its potential role in neuropathogenesis. ACS Chem Neurosci. 2020;11(13):1887–99.
    1. Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: Lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020;477(3):359–72.
    1. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through post-mortem core biopsies. Mod Pathol. 2020;33:1007–14.
    1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–22.
    1. Stefano GB, Esch T, Kream RM. Potential immunoregulatory and antiviral/SARS-CoV-2 activities of nitric oxide. Med Sci Monit. 2020;26:e925679.
    1. Shao C, Liu H, Meng L, et al. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: A case report. Hum Pathol. 2020;101:82–88.
    1. Hsia CC, Hyde DM, Weibel ER. Lung structure and the intrinsic challenges of gas exchange. Compr Physiol. 2016;6(2):827–95.
    1. Miesbach W, Makris M. COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26 1076029620938149.
    1. McFadyen JD, Stevens H, Peter K. The Emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571–87.
    1. Hui DS, Wong KT, Ko FW, et al. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest. 2005;128:2247–61.
    1. Ngai JC, Ko FW, Ng SS, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15:543–50.
    1. Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8.
    1. Chang YC, Yu CJ, Chang SC, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: Evaluation with thin-section CT. Radiology. 2005;236:1067–75.
    1. Wu X, Dong D, Ma D. Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS) Med Sci Monit. 2016;22:2793–99.
    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. .
    1. Cheung OY, Chan JWM, Ng CK, et al. The spectrum of pathological changes in severe acute respiratory syndrome (SARS) Histopathology. 2004;45:119–24.
    1. Zhao X, Nicholls JM, Chen Y-G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J Biol Chem. 2008;283:3272–3280.
    1. Zuo W, Zhao X, Chen YG. SARS coronavirus and lung fibrosis. In: Lal S, editor. Molecular Biology of the SARS-Coronavirus. Berlin and Heidelberg: Springer; 2010. pp. 247–58.
    1. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3–11.
    1. Chang CK, Hou MH, Chang CF, et al. The SARS coronavirus nucleocapsid protein-forms and functions. Antiviral Res. 2014;103:39–50.
    1. Chiappelli F. Towards neuro-CoViD-19. Bioinformation. 2020;16(4):288–92.
    1. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;24:1–9.
    1. Tsai LK, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan. 2005;14(3):113–19.
    1. Tsai LK, Hsieh ST, Chao CC, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol. 2004;61(11):1669–73.
    1. Lau KK, Yu WC, Chu CM, et al. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis. 2004;10(2):342–44.
    1. Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): A report from China. J Pathol. 2003;200(3):282–89.
    1. Xu J, Zhong S, Liu J, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine Mig in pathogenesis. Clin Infect Dis. 2005;41(8):1089–96.
    1. Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75.
    1. Barrantes FJ. Central nervous system targets and routes for SARS-CoV-2: Current views and new hypotheses. ACS Chem Neurosci. 2020;11(18):2793–803.
    1. Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: Identification of cell types and trends with age. ACS Chem Neurosci. 2020;11(11):1555–62.
    1. Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6(31):eabc5801.
    1. McCray PB, Jr, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–21.
    1. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology. 2003;315(1):20–33.
    1. Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213(5):712–22.
    1. Xiao L, Haack KK, Zucker IH. Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 signaling. Am J Physiol Cell Physiol. 2013;304(11):C1073–79.
    1. Dubé M, Le Coupanec A, Wong AHM, et al. Axonal transport enables neuron-to-neuron propagation of human Coronavirus OC43. J Virol. 2018;92(17):e00404–18.
    1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 92(6):552–55. 202.
    1. Li YC, Bai WZ, Hirano N, et al. Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells. Virus Res. 2012;163(2):628–35.
    1. Berth SH, Leopold PL, Morfini GN. Virus-induced neuronal dysfunction and degeneration. Front Biosci (Landmark Ed) 2009;14:5239–59.
    1. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) J Med Virol. 2020;92(7):699–702.
    1. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–98.
    1. Desforges M, Le Coupanec A, Brison E, et al. Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv Exp Med Biol. 2014;807:75–96.
    1. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–24.
    1. Nicholls JM, Butany J, Poon LL, et al. Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med. 2006;3(2):e27.
    1. Spiegel M, Schneider K, Weber F, et al. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J Gen Virol. 2006;87(Pt 7):1953–60.
    1. Trojanowicz B, Ulrich C, Kohler F, et al. Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. Nephrol Dial Transplant. 2017;32(2):287–98.
    1. Abassi Z, Knaney Y, Karram T, Heyman SN. The lung macrophage in SARS-CoV-2 infection: A friend or a foe? Front Immunol. 2020;11:1312.
    1. Jose RJ, Manuel A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–47.
    1. The BASE Medicine Task Force. Facts and recommendations of SARS-CoV-2 and COVID-19: An update. Science Insights. 2020;35(1):194–215.
    1. Kremer S, Lersy F, de Sèze J, et al. Brain MRI findings in severe COVID-19: A retrospective observational study. Radiology. 2020;16:202222.
    1. Wu K, Zou J, Chang HY. RNA-GPS predicts SARS-CoV-2 RNA localization to host mitochondria and nucleolus. Cell Syst. 2020;11(1):102–108.e3.
    1. Shenoy S. Coronavirus (Covid-19) sepsis: Revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. Inflamm Res. 2020;7:1–9.
    1. Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol. 2020;319(2):C258–67.
    1. Zhang AJ, Lee AC, Chu H, et al. SARS-CoV-2 infects and damages the mature and immature olfactory sensory neurons of hamsters. Clin Infect Dis. 2020 [Online ahead of print]
    1. Aghagoli G, Gallo Marin B, Katchur NJ, et al. Neurological involvement in COVID-19 and potential mechanisms: A review. Neurocrit Care. 2020;13:1–10.
    1. Thomson BJ. Viruses and apoptosis. Int J Exp Pathol. 2001;82(2):65–76.
    1. Nainu F, Shiratsuchi A, Nakanishi Y. Induction of apoptosis and subsequent phagocytosis of virus-infected cells as an antiviral mechanism. Front Immunol. 2017;8:1220.
    1. Richard A, Tulasne D. Caspase cleavage of viral proteins, another way for viruses to make the best of apoptosis. Cell Death Dis. 2012;3:e277.
    1. Shojaei S, Suresh M, Klionsky DJ, et al. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway. Virulence. 2020;11(1):805–10.
    1. Vallamkondu J, John A, Wani WY, et al. SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165889.
    1. Lukiw WJ, Pogue A, Hill JM. SARS-CoV-2 infectivity and neurological targets in the brain. Cell Mol Neurobiol. 2020;25:1–8.
    1. Trepson WL. Risk factors for Alzheimer’s disease. Science Insights. 2020;32(2):125–32.
    1. Sochocka M, Zwolińska K, Leszek J. The infectious etiology of Alzheimer’s disease. Curr Neuropharmacol. 2017;15(7):996–1009.
    1. Calderón-Garcidueñas L, Torres-Jardón R, Franco-Lira M, et al. Environmental nanoparticles, SARS-CoV-2 brain involvement, and potential acceleration of Alzheimer’s and Parkinson’s diseases in young urbanites exposed to air pollution. J Alzheimers Dis. 2020 [Online ahead of print]
    1. Chen X, Laurent S, Onur OA, et al. A systematic review of neurological symptoms and complications of COVID-19. J Neurol. 2020 [Online ahead of print]
    1. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
    1. Guo T, Zhang D, Zeng Y, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020;15(1):40.
    1. Beitz JM. Parkinson’s disease: A review. Front Biosci (Schol Ed) 2014;6:65–74.
    1. Das T, Hwang JJ, Poston KL. Episodic recognition memory and the hippocampus in Parkinson’s disease: A review. Cortex. 2019;113:191–209.
    1. Bezdicek O, Ballarini T, Buschke H, et al. Memory impairment in Parkinson’s disease: The retrieval versus associative deficit hypothesis revisited and reconciled. Neuropsychology. 2019;33(3):391–405.
    1. Krajcovicova L, Klobusiakova P, Rektorova I. Gray matter changes in Parkinson’s and Alzheimer’s disease and relation to cognition. Curr Neurol Neurosci Rep. 2019;19(11):85.
    1. Bernaus A, Blanco S, Sevilla A. Glia crosstalk in neuroinflammatory diseases. Front Cell Neurosci. 2020;14:209.
    1. Van Bulck M, Sierra-Magro A, Alarcon-Gil J, et al. Novel approaches for the treatment of Alzheimer’s and Parkinson’s disease. Int J Mol Sci. 2019;20(3):719.
    1. Compta Y, Parkkinen L, Kempster P, et al. The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson’s disease progression and related dementia. Neurodegener Dis. 2014;13(2–3):154–56.
    1. Sulzer D, Antonini A, Leta V, et al. COVID-19 and possible links with Parkinson’s disease and parkinsonism: From bench to bedside. NPJ Parkinsons Dis. 2020;6:18.
    1. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56(2):173–81.
    1. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–61.
    1. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis. 2020;71(15):889–90.
    1. Dell’Era V, Farri F, Garzaro G, et al. Smell and taste disorders during COVID-19 outbreak: Cross-sectional study on 355 patients. Head Neck. 2020;42(7):1591–96.
    1. Haddadi K, Ghasemian R, Shafizad M. Basal ganglia involvement and altered mental status: A unique neurological manifestation of coronavirus disease 2019. Cureus. 2020;12(4):e7869.
    1. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936.
    1. Kempuraj D, Selvakumar GP, Ahmed ME, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5–6):402–14.
    1. Zanin L, Saraceno G, Panciani PP, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien) 2020;162(7):1491–94.
    1. Palao M, Fernández-Díaz E, Gracia-Gil J, et al. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. 2020;45:102377.
    1. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol. 2000;74(19):8913–21.
    1. Boziki MK, Mentis AA, Shumilina M, et al. COVID-19 immunopathology and the central nervous system: Implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci. 2020;10(6):345.

Source: PubMed

3
Abonnere